Drug pricing policy the recent assessment.docVIP

 PAGE \* MERGEFORMAT 17 Drug pricing policy the recent assessment Throughout the past year the price of drugs Development and Reform Commission issued the policy, the core ideas can be summed up as follows - from the drugs began investigating the factory part of the cost of production, and then the middle of the provisions of circulation rate increases, limiting the circulation level, then according to pharmaceutical innovation levels in pricing, Finally, according to a Drug Pusher come ‘normal profit under protection of pharmaceutical companies’ retail prices. Judging from the current trends, Development and Reform Commission on the one hand to expand the breadth of price controls for drugs, on the other hand, it is to increase control efforts, expectations on the part of the whole control drug prices. Should be said that many people for the Development and Reform Commission itself and the practice of what can be achieved in this series have great expectations for the effectiveness of the following reasons: All the price data are after detailed investigation, scientific proof obtained from drug production to the Drug retail, the price of every aspect of the development was so clear that not only guarantee the various aspects of the normal profits, while standardizing the survival of the enterprise environment, to clean the market order, but also to reduce drug prices, and better satisfy the people’s people’s drug use demand, we are indeed serve multiple purposes, benefits the country and the good. However, things are really that simple? Through this unified management, drug prices would come down, or that the state and the people as well as reduce the medical burden of it? Hope is good, but the practice was real wrong, to put it completely that the source of error lies in the fact that the ‘cost’ determines the final product of the ‘price’ - the cost of raw materials, auxiliary materials costs, production costs and a series of cost - , plus the various cost